tradingkey.logo

Dare Bioscience Inc

DARE
查看詳細走勢圖
2.170USD
+0.010+0.46%
收盤 12/24, 16:00美東報價延遲15分鐘
30.23M總市值
虧損本益比TTM

Dare Bioscience Inc

2.170
+0.010+0.46%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

+0.46%

5天

-4.82%

1月

+22.60%

6月

-17.80%

今年開始到現在

-30.45%

1年

-32.19%

查看詳細走勢圖

TradingKey Dare Bioscience Inc股票評分

單位: USD 更新時間: 2025-12-24

操作建議

Dare Bioscience Inc當前公司基本面數據相對健康,增長潛力較大。當前估值合理,在藥品行業排名93/158位。機構持股佔比非常高,近一個月多位分析師給出公司評級為買入。最高目標價10.75。中期看,股價處於平穩狀態。近一個月,市場表現很強,技術面評分較高,但很強的走勢沒有得到基本面的印證。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Dare Bioscience Inc評分

相關信息

行業排名
93 / 158
全市場排名
255 / 4562
所屬行業
藥品

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

分析師目標

基於 4 分析師
買入
評級
10.750
目標均價
+484.24%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Dare Bioscience Inc亮點

亮點風險
Dare Bioscience, Inc. is a biopharmaceutical company. The Company's programs target unmet needs in women's health, primarily in the areas of contraception, sexual health, pelvic pain, fertility, infectious disease, vaginal health and menopause. Its product includes XACIATO (clindamycin phosphate) vaginal gel 2%. XACIATO is a single-dose prescription medication for the treatment of bacterial vaginosis in females 12 years of age and older. Its other product candidates include Ovaprene, Sildenafil Cream, and DARE-HRT1. Ovaprene is an investigational, hormone-free, monthly intravaginal contraceptive. Sildenafil Cream is a novel cream formulation of sildenafil for the treatment of female sexual arousal disorder; and DARE-HRT1 is an intravaginal ring designed to deliver a combination of menopausal hormone therapy, bio-identical 17b-estradiol and progesterone together, continuously over a 28-day period for the treatment of moderate to severe vasomotor symptoms, also known as hot flashes.
業績增長期
公司處於發展階段,最新年度總收入9.78K美元
估值合理
公司最新PE估值-1.19,處於3年歷史合理位
先鋒集團持倉
明星投資者先鋒集團持倉,最新持倉394.90K股
活躍度降低
近期活躍度降低,過去20天平均換手率-0.66

Dare Bioscience Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Dare Bioscience Inc簡介

Dare Bioscience, Inc. is a biopharmaceutical company. The Company's programs target unmet needs in women's health, primarily in the areas of contraception, sexual health, pelvic pain, fertility, infectious disease, vaginal health and menopause. Its product includes XACIATO (clindamycin phosphate) vaginal gel 2%. XACIATO is a single-dose prescription medication for the treatment of bacterial vaginosis in females 12 years of age and older. Its other product candidates include Ovaprene, Sildenafil Cream, and DARE-HRT1. Ovaprene is an investigational, hormone-free, monthly intravaginal contraceptive. Sildenafil Cream is a novel cream formulation of sildenafil for the treatment of female sexual arousal disorder; and DARE-HRT1 is an intravaginal ring designed to deliver a combination of menopausal hormone therapy, bio-identical 17b-estradiol and progesterone together, continuously over a 28-day period for the treatment of moderate to severe vasomotor symptoms, also known as hot flashes.
公司代碼DARE
公司Dare Bioscience Inc
CEOJohnson (Sabrina Martucci)
網址https://www.darebioscience.com/

常見問題

Dare Bioscience Inc(DARE)的當前股價是多少?

Dare Bioscience Inc(DARE)的當前股價是 2.170。

Dare Bioscience Inc 的股票代碼是什麼?

Dare Bioscience Inc的股票代碼是DARE。

Dare Bioscience Inc股票的52週最高點是多少?

Dare Bioscience Inc股票的52週最高點是9.190。

Dare Bioscience Inc股票的52週最低點是多少?

Dare Bioscience Inc股票的52週最低點是1.610。

Dare Bioscience Inc的市值是多少?

Dare Bioscience Inc的市值是30.23M。

Dare Bioscience Inc的淨利潤是多少?

Dare Bioscience Inc的淨利潤為-4.05M。

現在Dare Bioscience Inc(DARE)的股票是買入、持有還是賣出?

根據分析師評級,Dare Bioscience Inc(DARE)的總體評級為買入,目標價格為10.750。

Dare Bioscience Inc(DARE)股票的每股收益(EPS TTM)是多少

Dare Bioscience Inc(DARE)股票的每股收益(EPS TTM)是-1.824。
KeyAI